%0 Journal Article
%T Targeting HER-2 in gastric cancer ¨C incorporation of trastuzumab into the treatment of operable disease
%A Bystricky B
%A Okines AFC
%A Cunningham D
%J Gastrointestinal Cancer: Targets and Therapy
%D 2011
%I 
%R http://dx.doi.org/10.2147/GICTT.S18495
%X rgeting HER-2 in gastric cancer ¨C incorporation of trastuzumab into the treatment of operable disease Review (2611) Total Article Views Authors: Bystricky B, Okines AFC, Cunningham D Published Date July 2011 Volume 2011:1 Pages 41 - 52 DOI: http://dx.doi.org/10.2147/GICTT.S18495 Branislav Bystricky, Alicia FC Okines, David Cunningham Royal Marsden Hospital NHS Trust, Sutton and London, UK Abstract: Gastric cancer is the fourth most common malignancy and second leading cause of cancer death world-wide, and is therefore a significant global health problem. Radical surgery with a D2 lymph node dissection is an accepted standard approach, and is a key component of multimodality therapy. Perioperative chemotherapy significantly improves 5-year overall survival compared with surgery alone. A significant improvement in overall survival has also been demonstrated with postoperative 5-fluorouracil-based chemoradiotherapy and adjuvant oral S-1 chemotherapy; approaches commonly used widely in North America and Japan, respectively. Approximately 10% to 20% of gastric cancers and 20% to 30% of esophago-gastric junction cancers are HER-2 positive. The effect of HER-2 overexpression and HER-2 gene amplification on gastric cancer prognosis remains unresolved. The results of the first randomized phase III trial of trastuzumab, a monoclonal antibody directed at the HER-2 receptor, in patients with metastatic gastric cancer were reported recently. Response rate, median progression-free survival, and median overall survival were all significantly improved with the addition of trastuzumab to a cisplatin/fluoropyrimidine doublet. Evaluation of trastuzumab in HER-2 positive operable esophago-gastric cancer is now underway. Lapatinib, a small-molecule inhibitor targeting EGFR and HER-2 is well established in the treatment of trastuzumab-refractory HER-2 positive breast cancer and phase III trials in advanced esophago-gastric cancers are ongoing. Novel, small molecule pan-HER inhibitors have entered early phase evaluation and the antibody-drug conjugate, trastuzumab-DM1, and pertuzumab, a monoclonal antibody which prevents HER-2/HER-3 dimerization, are currently undergoing phase II/III evaluation in breast cancer. It is our hope that advances in the targeted treatment of HER-2 positive breast cancer will be replicated in HER-2 positive esophago-gastric cancers.
%K gastric cancer
%K adjuvant
%K perioperative
%K chemotherapy
%K trastuzumab
%K HER-2
%U https://www.dovepress.com/targeting-her-2-in-gastric-cancer-ndash-incorporation-of-trastuzumab-i-peer-reviewed-article-GICTT